Register Login

CELCUITY INC. (CELC)

(19% Negative) CELCUITY INC. (CELC) Announces Delay in patients Trials for multiple solid tumor indications Due to Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 26, 2026, 12:35 p.m.

    📋 CELCUITY INC. (CELC) - Clinical Trial Update

    Filing Date: 2026-08-26

    Accepted: 2026-08-26 08:35:14

    Event Type: Clinical Trial Update

    Event Details:

    CELCUITY INC. (CELC) Announces Clinical Trial Update CELCUITY INC. (CELC) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients
    • Diseases/Conditions: multiple solid tumor indications, hormone
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process, Regulatory Timeline
    • Collaboration: New Drug Application

    🔬 Clinical Development Pipeline (CELCUITY INC.):

    Product Type Development Stage Therapeutic Area Source
    Arm B: Ribociclib + Fulvestrant Other Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Arm D: Ribociclib + Letrozole Other Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Darolutamide Other Phase PHASE1 mCRPC (Metastatic Castration-resistant Prostate Cancer) ClinicalTrials.gov
    Arm C: Gedatolisib + Palbociclib + Letrozole Other Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Arm A: Gedatolisib + Palbociclib + Fulvestrant Other Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Fulvestrant Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Letrozole Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Palbociclib Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Gedatolisib Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    NERATINIB Other Phase PHASE2 Stage IV (Metastatic) Breast Cancer ClinicalTrials.gov
    Talazoparib Other Phase PHASE1 TNBC - Triple-Negative Breast Cancer ClinicalTrials.gov
    Capmatinib Other Phase PHASE1 Metastatic Breast Cancer ClinicalTrials.gov
    Alpelisib Other Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Arm B: Palbociclib or Ribociclib + Fulvestrant Other Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant Other Phase PHASE3 Breast Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CELCUITY INC.
    • Ticker Symbol: CELC

Search

News categories